Apellis Stock Disappears From Nasdaq as Biogen $41 Billion Buyout Faces Final Hurdle
Biogen has finished its acquisition of Apellis Pharmaceuticals, and trading in the APLS ticker has ceased. Apellis is now a wholly owned unit of Biogen after the buyout.
